Al Stewart
Pfizer (United States)(US)PRX Research
Publications by Year
Research Areas
SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Computational Drug Discovery Methods, Epigenetics and DNA Methylation, Viral gastroenteritis research and epidemiology
Most-Cited Works
- → An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19(2021)1,854 cited
- → Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition(2012)193 cited
- → Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants(2022)170 cited
- → Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance(2016)160 cited
- → Targeting S-adenosylmethionine biosynthesis with a novel allosteric inhibitor of Mat2A(2017)131 cited
- → Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1(2020)77 cited
- → The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase(2017)61 cited
- → Structural basis for Nirmatrelvir in vitro efficacy against SARS-CoV-2 variants(2022)26 cited
- → Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main Protease(2025)16 cited